Patent Assignment
Reel/Frame 029195/0555
Amylin Pharmaceuticals, Llc Assigns an Equal and Undivided One-Half of Its Entire Right, Title and Interest to Astrazeneca Pharmaceuticals Lp
Recorded: 2012-10-26
Pages: 70
Assignor
AMYLIN PHARMACEUTICALS, LLC
Executed: 2012-09-19
Assignee
ASTRAZENECA PHARMACEUTICALS LP
1800 CONCORD PIKE, WILMINGTON, DELAWARE, 19803
Covered Properties
(123)
Glp-1 Receptor Agonists to Treat Pancreatitis
PCT:
PCT/US2011/039494 ↗
Microcrystalline Y Receptor Agonists
PCT:
PCT/US2011/043420 ↗
Glp-1 Receptor Agonist Compounds Having Stabilized Regions
PCT:
PCT/US2011/045614 ↗
C-Terminal Amidation of Polypeptides
PCT:
PCT/US2011/050754 ↗
Engineered Polypeptides Having Enhanced Duration of Action
PCT:
PCT/US2011/053770 ↗
Highly Soluble Leptins
PCT:
PCT/US2011/053774 ↗
Engineered Polypeptides Having Enhanced Duration of Action
PCT:
PCT/US2011/053786 ↗
Amylin Peptides and Derivatives and Uses Thereof
PCT:
PCT/US2012/039431 ↗
Long Duration Dual Hormone Conjugates
PCT:
PCT/US2012/039440 ↗
Gel Compositions
PCT:
PCT/US2012/041519 ↗
Methods for Treating Diabetes with Extended Release Formulations of Glp-1 Receptor Agonists
PCT:
PCT/US2012/043615 ↗
Engineered Polypeptides Having Enhanced Duration of Action and Reduced Immunogenicity
PCT:
PCT/US2012/045398 ↗
Engineered Polypeptides Having Enhanced Duration of Action with Reduced Immunogenicity
PCT:
PCT/US2012/045451 ↗
Amylin-Calcitonin Chimeric Peptides Conugated to Duration Enchancing Moieties
PCT:
PCT/US2012/060637 ↗
Novel Amylin Antagonist Peptides and Uses Therefor
Patent:
5,580,953 →
Application:
07/794,288 →
Production of Peptide Amides
Patent:
5,503,989 →
Application:
07/927,755 →
Selective Amylin Antagonist Peptides and Uses Therefor
Patent:
5,625,032 →
Application:
08/096,172 →
Polypeptide and Protein Derivatives and Process for Their Preparation
Patent:
6,673,347 →
Application:
08/241,687 →
Methods and Compositions for Treatment of Diabetes Mellitus, Hypoglycemia, and Other Conditions
Patent:
5,508,260 →
Application:
08/259,755 →
Method and Composition for Treatment of Insulin Requiring Mammals
Patent:
5,814,600 →
Application:
08/259,762 →
Methods & Compositions for Treatment of Diabetes Mellitus, Hypoglycemia & Other Conditions
Patent:
5,527,771 →
Application:
08/260,493 →
Methods for Regulating Gastrointestinal Motility
Patent:
6,114,304 →
Application:
08/302,069 →
Treatment of Diabetes Mellitus
Patent:
5,641,744 →
Application:
08/341,342 →
Amylin Activity Assays
Patent:
6,048,514 →
Application:
08/422,747 →
Amylin Agonist Peptides and Uses Therefor
Patent:
5,686,411 →
Application:
08/447,849 →
Methods for Regulating Gastrointestinal Motility
Patent:
5,795,861 →
Application:
08/471,675 →
Appetite Regulating Compositions
Patent:
5,739,106 →
Application:
08/477,727 →
Treatment of Type Ii Diabetes Mellutis with Amylin Agonists
Patent:
6,143,718 →
Application:
08/483,188 →
Polyoxime Compounds and Their Preparation
Patent:
6,217,873 →
Application:
08/537,928 →
Methods and Compositions for Treating Pain with Amylin or Agonists Thereof
Patent:
5,677,279 →
Application:
08/767,169 →
Method for Treating or Preventing Gastritis Using Amylin or Amylin Agonists
Methods for Treating Obesity
Methods for Regulating Gastrointestinal Motility
Patent:
6,858,576 →
Application:
08/908,867 →
Use of Exendins and Agonists Thereof for the Reduction of Food Intake
Formulations for Amylin Agonist Peptides
Polynucleotides Encoding Proexendin, and Methods and Uses Thereof
Patent:
6,723,530 →
Application:
09/019,172 →
Novel Anti-Diabetic Peptides
Patent:
6,087,334 →
Application:
09/138,056 →
Metabolic Intervention with Glp-1 to Improve the Function of Ischemic and Reperfused Tissue
Patent:
6,284,725 →
Application:
09/302,596 →
Use of Exendins and Agonists Thereof for the Treatment of Gestational Diabetes Mellitus
Patent:
6,506,724 →
Application:
09/323,867 →
Lipid Matrix-Assisted Chemical Ligation and Synthesis of Membrane Polypeptides
Patent:
6,451,543 →
Application:
09/384,302 →
Novel Exendin Agonist Compounds
Patent:
7,220,721 →
Application:
09/554,531 →
Novel Exendin Agonist Compounds
Patent:
7,223,725 →
Application:
09/554,533 →
Modified Exendins and Exendin Agonists
Patent:
6,924,264 →
Application:
09/561,226 →
Methods for Regulating Gastrointestinal Motility
Patent:
6,608,029 →
Application:
09/576,062 →
Novel Mixed Amylin Activity Compounds
Patent:
6,936,584 →
Application:
09/622,104 →
Inotropic and Diuretic Effects of Exendin and Glp-1
Patent:
6,703,359 →
Application:
09/622,105 →
Human Appetite Control by Glucagon-Like Peptide Receptor Binding Compounds
Patent:
6,998,387 →
Application:
09/646,433 →
Exendin Improves Beta-Cell Response in Subjects with Impaired Glucose Tolerance
Patent:
7,265,087 →
Application:
09/719,410 →
Uncoupling Protein 4 (Ucp-4)
Patent:
6,602,694 →
Application:
09/743,847 →
Treatment of Acute Coronary Syndrome with Glp-1
Novel Exendin Agonist Formulations and Methods of Administration Thereof
Patent:
6,902,744 →
Application:
09/889,330 →
Methods for Glucagon Suppression
Patent:
6,872,700 →
Application:
09/889,331 →
Treatment of Hibernating Myocardium and Diabetic Cardiomyopathy with a Glp-1 Peptide
Methods of Treating Obesity Using Pyy[3-36]
Compositions and Methods for Treating Peripheral Vascular Disease
Formulations for Amylin Agonist Peptides
Novel Exendin Agonist Compounds
Patent:
7,157,555 →
Application:
10/181,102 →
Exendins, Exendin Agonists, and Methods for Their Use
Methods and Compositions for Treating Polycystic Ovary Syndrome
Pseudo Native Chemical Ligation
Nucleophile-Stable Thioester Generating Compounds, Methods of Production and Use
Use of Amylin Agonists to Modulate Triglycerides
Application:
10/337,979 →
Publication:
US 2003/0130177
Native Chemical Ligation with Three or More Components
Chemical Peptide Ligation with Three or More Components
Post-Cleavage Sulfur Deprotection for Convergent Protein Synthesis by Chemical Ligation
Carboxy Protection Strategies for Acidic C-Terminal Amino Acids in Chemical Ligation of Oligopeptides
Water-Soluble Thioester and Selenoester Compounds and Methods for Making and Using the Same
Novel Methods and Compositions for Enhanced Transmucosal Delivery of Peptides and Proteins
Amylin Family Peptides
Methods and Compositions for Treating Polycystic Ovary Syndrome
Treatment of Pancreatitis with Amylin
Treatment of Cardiac Arrhythmias with Glp-1 Receptor Ligands
Method for Enhanced Parenteral Nutrition
Methods for Affecting Body Composition
Pharmaceutical Compositions Containing Exendins
Exendins and Exendin Agonists for Weight Reduction and Obesity
Exendin Pharmaceutical Compositions
Metabolic Intervention with Glp-1 or Its Biologically Active Analogues to Improve the Function of the Ischemic and Reperfused Brain
Patent:
41,288 →
Application:
10/913,309 →
Pancreatic polypeptide family motifs and polypeptides comprising the same
Hybrid Polypeptides Having Glucose Lowering Activity
Exendin Analog Formulations
Treatment of Gestational Diabetes
Pancreatic Polypeptide Family Motifs, Polypeptides and Methods Comprising the Same
Transmucosal delivery of peptides and proteins
Application:
11/628,123 →
Publication:
US 2009/0069226
Amylin Family Polypeptide-6 (Afp-6) Analogs and Methods of Making and Using Them
Methods for treating obesity and obesity related diseases and disorders
Application:
11/665,675 →
Publication:
US 2009/0156474
Gip Analog and Hybrid Polypeptides with Selectable Properties
Gip Analog and Hybrid Polypeptides with Selectable Properties
Use of Glp-1 and Agonists Thereof to Prevent Cardiac Myocyte Apoptosis
Application:
11/857,951 →
Publication:
US 2009/0264352
Amylin Agonist for Treating Depression, Anxiety Disorder and Schizophrenia
Methods of Controlling Binge Eating Disorders
Pharmaceutical Formulations Comprising Incretin mimetic Peptide and Aprotic Polar Solvent
Application:
11/910,723 →
Publication:
US 2008/0200383
Use of Exendin and Analogs Thereof To Delay or Prevent Cardiac Remodeling
Methods of Treating Obesity with two Different Anti-Obesity Agents
Hybrid Polypeptides with Selectable Properties
Application:
12/063,420 →
Publication:
US 2009/0286723
Exendin-4 to Treat Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver Disease
Compositions and Methods for Treating Obesity and Related Metabolic Disorders
Application:
12/097,737 →
Publication:
US 2009/0209460
Amylin Agonists for Treating Cognitive Impairments
Application:
12/295,259 →
Publication:
US 2009/0181890
Novel Exendin and Glp-1 Peptides and Their Uses
Application:
12/301,199 →
Publication:
US 2010/0029554
DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties
Neuromedin and Fn-38 Peptides for Treating Psychiatric Diseases
Formulation Delivery Device
Mixing Tool
Drug Delivery Device
Pen Injection Device and Method of Using Same
Peptide-Peptidase-Inhibitor Conjugates and Methods of Making and Using Same
Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same
Glp-1 Receptor Agonist Bioassays
Exendins to Lower Cholesterol and Triglycerides
Application:
12/992,060 →
Publication:
US 2011/0263496
Sustained Release Formulations Using Non-Aqueous Carriers
Methods for Treating Diabetes and Reducing Body Weight
Methods of using GLP-1 receptor agonists to treat pancreatitis
Methods for Affecting Body Composition Using Amylin Agonists
N-Terminus Conformationally Constrained Glp-1 Receptor Agonist Compounds
Amylin Agonist Compounds for Estrogen-Deficient Mammals
Application:
13/263,070 →
Publication:
US 2012/0071401
Amylin Family Peptides and Methods for Making and Using Them
Application:
13/445,803 →
Publication:
US 2012/0196799
Polypeptide Conjugate
Application:
13/511,201 →
Publication:
US 2014/0066370
Hypodermic Needle Assembly Having a Transition Hub for Enhancing Fluid Dynamics and Microsphere Injectability
Application:
13/520,965 →
Publication:
US 2013/0096531
Engineered Polypeptides Having Enhanced Duration of Action with Reduced Immunogenicity
Application:
61/585,577 →
Engineered Polypeptides
Application:
61/616,906 →
Transmucosal Delivery of Engineered Polypeptides
Application:
61/616,961 →
Site-Specific Enzymatic Modification of Exendins and Analogs Thereof
Application:
61/637,393 →
Methods for Treating Diabetes with Extended Release Formulations of GLP-1 Receptor Agonists
Application:
61/657,595 →
Related Assignments
(24)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jul 3, 2012
From: EKBLAD, CAROLINE
To: AMYLIN PHARMACEUTICALS, INC.; AFFIBODY AB
Reel/Frame 028486/0185 →
Assignment of Assignor's Interest
Jul 3, 2012
From: ERICKSON, MARY; LITZINGER, DAVID C.; GHOSH, SOUMITRA S.; GUO, ZIJIAN
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 028486/0125 →
Assignment of Assignor's Interest
Jul 3, 2012
From: EKBLAD, CAROLINE
To: AMYLIN PHARMACEUTICALS, INC.; AFFIBODY AB
Reel/Frame 028486/0860 →
Assignment of Assignor's Interest
Jul 3, 2012
From: ERICKSON, MARY; LITZINGER, DAVID C.; GHOSH, SOUMITRA S.; GUO, ZIJIAN
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 028486/0840 →
Assignment of Assignor's Interest
Jul 11, 2012
From: SUN, CHENGZAO; FOROOD, BEHROUZ BRUCE
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 028532/0199 →
Assignment of Assignor's Interest
Jul 11, 2012
From: ALFARO-LOPEZ, JOSUE; SHARMA, ABHINANDINI; SOARES, CHRISTOPHER J.; COATS, EUGENE
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 028532/0248 →
Assignment of Assignor's Interest
Jul 18, 2012
From: SUN, CHENGZAO; FOROOD, BEHROUZ BRUCE; LUO, GARY; GHOSH, SOUMITRA S.
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 028575/0671 →
Assignment of Assignor's Interest
Jul 23, 2012
From: REN, STEVEN SHIJUN
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 028616/0913 →
Assignment of Assignor's Interest
Aug 7, 2012
From: SUN, CHENGZAO; SAMANT, MANOJ P.
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 028740/0778 →
Assignment of Assignor's Interest
Sep 18, 2012
From: CIRINCIONE, BRENDA B.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 028981/0746 →
Assignment of Assignor's Interest
Sep 18, 2012
From: ZIERHUT, MATTHEW L.
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 028981/0618 →
Change of Name
Sep 18, 2012
From: AMYLIN PHARMACEUTICALS, INC.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 029004/0251 →
Assignment of Assignor's Interest
Sep 28, 2012
From: ERICKSON, MARY; LITZINGER, DAVID C.; GUO, ZIJIAN; ROTH, JONATHAN DAVID
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 029050/0166 →
Change of Name
Sep 28, 2012
From: AMYLIN PHARMACEUTICALS, INC.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 029058/0367 →
Assignment of Assignor's Interest
Sep 28, 2012
From: ERICKSON, MARY
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 029050/0086 →
Assignment of Assignor's Interest
Sep 28, 2012
From: GHOSH, SOUMITRA S.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 029050/0265 →
Change of Name
Oct 25, 2012
From: AMYLIN PHARMACEUTICALS, INC.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 029198/0295 →
Change of Name
Oct 25, 2012
From: AMYLIN PHARMACEUTICALS, INC.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 029198/0414 →
Change of Name
Oct 25, 2012
From: AMYLIN PHARMACEUTICALS, INC.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 029198/0396 →
Change of Name
Dec 11, 2012
From: AMYLIN PHARMACEUTICALS, INC.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 029449/0674 →
Change of Name
Dec 11, 2012
From: AMYLIN PHARMACEUTICALS, INC.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 029449/0656 →
Amylin Pharmaceuticals, Llc Assigns an Equal and Undivided One-Half of Its Entire Right, Title and Interest to Astrazeneca Pharmaceuticals Lp
Jan 14, 2013
From: AMYLIN PHARMACEUTICALS, LLC
To: ASTRAZENECA PHARMACEUTICALS LP
Reel/Frame 029621/0235 →
Amylin Pharmaceuticals, Llc Assigns an Equal and Undivided One-Half of Its Entire Right, Title and Interest to Astrazeneca Pharmaceuticals Lp
Jan 14, 2013
From: AMYLIN PHARMACEUTICALS, LLC
To: ASTRAZENECA PHARMACEUTICALS LP
Reel/Frame 029621/0076 →
Assignment of Assignor's Interest
Sep 11, 2013
From: ERICKSON, MARY; LITZINGER, DAVID C.; GHOSH, SOUMITRA S.; GUO, ZIJIAN
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 031187/0018 →